US Bancorp’s Yarrow Bioscience YARW Stock Holding History

US Bancorp’s Portfolio YARW Stock Details YARW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-89	Closed	-$10.4K	–	4109
2023 Q4	$10.4K	Hold	89	–	–	﹤0.01%	3307
2023 Q3	$18K	Buy	+89	New	+$19.4K	﹤0.01%	2936

Other funds holding YARW

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

PHP

Parkman Healthcare Partners Stamford, Connecticut $977M AUM 110.37% 1-Year Est. Return

DSC Advisors Chicago, Illinois $11M AUM 5.88% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

AlphaCentric Advisors San Juan, Puerto Rico $118M AUM

EAM

Exome Asset Management New York $162M AUM 259.04% 1-Year Est. Return

SSA

Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

US Bancorp's YARW Position: Q1 2024 in Review

US Bancorp sold out of Yarrow Bioscience (YARW) in Q1 2024, closing a stake of 89 shares — an estimated $10.4K sold.

US Bancorp first reported a position in YARW in Q3 2023 and held it in 2 quarters. The position peaked at $18K in Q3 2023. 30 funds tracked by Wall St. Rank hold YARW as of Q1 2024.

US Bancorp reported no remaining Yarrow Bioscience position as of Q1 2024 after selling out during the quarter.
US Bancorp sold 89 Yarrow Bioscience shares in Q1 2024, an estimated $10.4K.
US Bancorp first reported a position in Yarrow Bioscience in Q3 2023 and held it in 2 quarters.
US Bancorp's Yarrow Bioscience position peaked at $18K in Q3 2023.
30 funds tracked by Wall St. Rank held Yarrow Bioscience as of Q1 2024.

Based on US Bancorp's 13F filing for Q1 2024, filed 8 May 2024.